Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM: A multicenter comparison study

Diabetes Care

Volumn 21, Issue 4, 1998, Pages 477-481

  Tikkanen, Mattl J ^a,g   Laakso, Markku ^b   Ilmonen, Marja ^a   Helve, Eero ^c   Kaarsalo, Esko ^d   Kllkki, Esa ^e   Saltevo, Juha ^f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c MERCK ANIMAL HEALTH   (United States)

^d Loimaa District Hospital

^e Kuusankoski District Hospital

^f Central Finland Health Care District   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MIXTURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FINLAND; GEMFIBROZIL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; SIMVASTATIN; TIME FACTORS; TRIGLYCERIDES;

EID: 0031919908     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.4.477     Document Type: Article

References (26)

1. Pyörälä K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463-524, 1987
2. Laakso M: Epidemiology of diabetic dyslipidemia. Diabetes Rev 3:408-422, 1995
3. Nikkilä EA: Plasma lipid and lipoprotein abnormalities in diabetes. In Diabetes and Heart Disease. Jarret RJ, Ed. Amsterdam, Elsevier, 1984, p. 133-167
4. Rönnemaa T, Laakso M, Kallio V, Pyörälä K, Marniemi J, Puukka P: Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients, Am J Epidemiol 130:632-645, 1989
5. World Health Organization: WHO Expert Committee on Diabetes Melittus. Second Report. Geneva, World Health Org., 1980 (Tech. Rep. Ser. no. 646)
6. American Diabetes Association: Detection and management of lipid disorders in diabetes (Consensus Statement). Diabetes Care 19(Suppl. 1):S96-S102, 1996
7. Lopes-Virella MF, Stone P, Ellis S, Colwell JA: Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 23:882-884, 1977
8. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low- density lipoprotein cholesterol without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
9. Lintott CJ, Scott RS, Sutherland WHF, Bremer JM, Shand BI, Frampton CM: Comparison of simvastatin vs. gemfibrozil therapy on lipid, glycaemic and haemorheologic parameters in type II diabetes mellitus. Diabetes Nutr Metab Clin Exp 5:183-189, 1992
10. Sweany AE, Shapiro DR, Tate AC, Goldberg RB, Stein EA: Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. Clin Ther 17:186-203, 1995
11. Öhrvall M, Uthell H, Johansson J, Vessby B: A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 44:212-217, 1995
12. Goldberg R, La Belle P, Zupkis R, Ronca P: Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol 66:16B-21B, 1990
13. Ojala J-P, Helve E, Tikkanen MJ: Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study Cardiology 77 (Suppl. 4):39-49, 1990
14. Tikkanen MJ, Bocanegra TS, Walker F, Cook T, the Simvastatin Study Group: Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol: a multicenter study. Am J Med 87:47S-53S, 1989
15. Tikkanen MJ, Helve E, Jäättelä A, Kaarsalo E, Lehtonen A, Malbecq W, Oksa H, Pääkkönen P, Salmi J, Veharanta T, Viikari J, Äärynen M, the Finnish Lovastatin Study Group: Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. Am J Cardiol 62:35J-43J, 1988
16. Garg A, Grundy SM: Management of dyslipidemia in NIDDM. Diabetes Care 13:153-169, 1990
17. Pyörälä K, Pedersen TR, KjekshusJ, Faergeman O, Olsson AG, Thorgeirsson G, for the Scandinavian Simvastatin Survival Study (4S) Group: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (45). Diabetes Care 20:614-620, 1997
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
19. Vinik AI, Colwell JA: Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Diabetes Care 16:37-44, 1993
20. Tilly-Kiesi M, Tikkanen MJ: Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil, J Intern Med 229:427-434, 1991
21. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853, 1996
22. Frick MH, Elo O, Haapa K, Heinonen O, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Mikkilä EA: The Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
23. Tikkanen MJ: Practical drug therapy for common hyperlipidaemias. Baillieres Clin Endoc Metab 4:719-742, 1990
24. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264:71-75, 1990
25. Shepherd J: Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 16:5-13, 1995
26. Vuorinen-Markkola H, Yki-Järvinen H, Taskinen MR: Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:161-166, 1993